Zacks Investment Research
17 Jun 2026, 11:51 UTC · 2h ago
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
17 Jun 2026, 11:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA has accepted the New Drug Application (NDA) for zilurgisertib for the treatment of fibrodysplasia ossificans progressiva (FOP) and granted it Priority Review status. — Priority Review significantly accelerates the timeline to potential commercialization, increasing the probability of near-term revenue for the developers.
+0.80Zilurgisertib demonstrated positive pivotal phase II results in the PROGRESS study, reducing the proportion of patients with new heterotopic ossification lesions. — Positive clinical data on a primary endpoint increases the likelihood of regulatory approval and validates the drug's efficacy.
+0.60The FDA is expected to deliver its decision regarding the NDA for zilurgisertib by September 26, 2026. — Provides a concrete catalyst date for investors to anticipate a binary outcome (approval or rejection).
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Mirum Pharmaceuticals (MIRM) holds the worldwide development and commercialization rights for zilurgisertib, which was licensed from Incyte Corporation (INCY). — Clarifies the commercial ownership and benefit structure between the two involved companies.
+0.20Which stocks this story touches
Reported positive pivotal phase II results and received FDA Priority Review status for zilurgisertib.
Reported positive pivotal phase II results and is the licensor of the drug receiving FDA Priority Review.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
11h ago
